Английский Финансы
16.07.2026 Читать источник
Аналитики TD Cowen повысили Dyne Therapeutics до «Купить» и выделили потенциал платформы FORCE
Компания Dyne Therapeutics получила рейтинг «Купить» от TD Cowen благодаря перспективам своей платформы FORCE в лечении нейромышечных заболеваний. Одновременно с этим биотех увеличил доступный капитал до 125 миллионов долларов после поправок к кредитному соглашению с Hercules Capital.
Перевод ИИ
Текст статьи доступен на языке оригинала.
Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.
Оригинальный контент
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now.
On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock. The firm stated that the company's Force platform has the potential to improve drug delivery in neuromuscular and CNS diseases by overcoming the related limitations.
Pressmaster/Shutterstock.com
Further, TD Cowen stressed the fact that the company's late-stage candidates offer the potential to become top-notch therapies. These include z-basivarsen, which targets myotonic dystrophy type 1, and z-rostudirsen, which is used for exon 51 Duchenne muscular dystrophy mutations.
On June 17, Dyne Therapeutics Inc. (NASDAQ:DYN) finalized amendments to its non-dilutive senior secured term loan arrangement with Hercules Capital. As part of the revised arrangement, $50 million had already been funded at the closing of this amendment. In addition to that, Dyne has the option to draw $50 million in term loan tranche, depending on some milestones that need to be achieved.
There were amendments made to the final term loan facility as well, which involved expanding the tranche by $25 million. This means that Dyne has access to $125 million in capital, at Hercules' discretion.
Dyne Therapeutics Inc. (NASDAQ:DYN) is a biotechnology company that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. It makes use of its FORCE platform to identify the root cause of a condition and currently has a strong pipeline of clinical and preclinical programs.
While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Аналитика ИИ и парсинга
Технические детали обнаружения, сопоставления и связывания статьи
Поисковый запрос
«TD Cowen повысил рейтинг Dyne Therapeutics до Купить потенциал платформы FORCE лечение нейромышечных заболеваний»
Запрос, сгенерированный ИИ для поиска статьи в веб-источниках
Связанные результаты поиска
Результаты поиска отсутствуют в БД
Парсер не сохранил результаты веб-поиска для этой статьи.